Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Encapsulation of MERS antigen into α-GalCer-bearing-liposomes elicits stronger effector and memory immune responses in immunocompetent and leukopenic mice

Masood Alam Khan, Arif Khan, Mohammad A. Alzohairy, Abdulmohsen M. Alruwetei, Mohammed A. Alsahtli, Khaled S. Allemaile, Faris Alrumithi, Ahmad Almatroud, Bader Y. Alhatlan, Osamah Al Ragaie, Ajamaluddin Malik

Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia
Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia
Department of Applied Medical Sciences, Applied College, Qassim University, Unayzah, Saudi Arabia
Department of Basic Medical Sciences, College of Medicine and Medical Sciences, Qassim University, Unayzah, Saudi Arabia
Department of Biochemistry, College of Science, King Saud University, Riyadh, Saudi Arabia

Article history:
Received 10 January 2022
Revised 22 April 2022
Accepted 21 May 2022
Available online 27 May 2022

Keywords:
Immunization
Liposome
MERS-CoV
NKT cell

Abstract

Objectives: Here, we prepared a liposome-based vaccine formulation containing Middle East Respiratory Syndrome Coronavirus papain-like protease (MERS-CoV-PLpro).

Methods: A persistent leukopenic condition was induced in mice by injecting cyclophosphamide (CYP) three days before each dose of immunization. Mice were immunized on days 0, 14 and 21 with α-GalCer-bearing MERS-CoV PLpro-encapsulated DPPC-liposomes (α-GalCer-MERS-PLpro-liposomes) or MERS-CoV PLpro-encapsulated DPPC-liposomes (MERS-PLpro-liposomes), whereas the antigen emulsified in Alum (MERS-PLpro-Alum) was taken as a control. On day 26, the blood was taken from the immunized mice to analyze IgG titer, whereas the splenocytes were used to analyze the lymphocyte proliferation and the level of cytokines. In order to assess the memory immune response, mice were given a booster dose after 150 days of the last immunization.

Results: The higher levels of MERS-CoV-PLpro-specific antibody titer, IgG2a and lymphocyte proliferation were noticed in mice immunized with α-GalCer-MERS-PLpro-liposomes. Besides, the splenocytes from mice immunized with α-GalCer-MERS-PLpro-liposomes produced larger amounts of IFN-γ as compared to the splenocytes from MERS-PLpro-liposomes or MERS-PLpro-Alum immunized mice. Importantly, an efficient antigen-specific memory immune response was observed in α-GalCer-MERS-PLpro-liposomes immunized mice.

Conclusions: These findings suggest that α-GalCer-MERS-PLpro-liposomes may substantiate to be a successful vaccine formulation against MERS-CoV infection, particularly in immunocompromised individuals.

© 2022 The Authors. Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Immunocompromised individuals have shown greater susceptibility to viral infections, including influenza virus, cytomegalovirus, Herpes simplex virus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) and Middle Eastern Respiratory Syndrome coronavirus (MERS-CoV) (Bosaeed and Kumar, 2018; Voia and Englund, 2015; Lai et al., 2020). MERS-CoV was first isolated in Saudi Arabia from a patient suffering from severe respiratory...
problems (Faridi, 2018). The healthcare workers are considered the major victims of MERS-CoV infection (Alshammari et al., 2018).

Upon activation with alpha-Galactosylceramide ($\alpha$-GalCer) NKT cells produce Th1 and Th2 cytokines as well (Brutkiewicz, 2006). The activation of NKT cells leads to the maturation of dendritic cells (DCs) and B cells (Fig. 1). NKT cells have shown critical role during viral infections, including Hepatitis B virus (HBV), Influenza A virus (IAV), Respiratory Syncytial virus (RSV) and Herpes Simplex virus (HSV) (Khan and Khan, 2021; Grubor-Bauk et al., 2003).

The immunization of immunocompromised individuals has been a big challenge owing to their poor immune response to antigens. Liposomes are effective as a potent immunoadjuvant due to their ability to stimulate the immune responses (Khan and Khan, 2021; Ahmad et al., 2001). Liposome-mediated delivery of MERS-CoV PLpro can stimulate antigen-specific immune responses (Khan et al., 2022). NKT cell-ligand alpha-Galactosylceramide ($\alpha$-GalCer) has the ability to equally stimulate B cells and T cells (Fig. 1). Moreover, $\alpha$-GalCer has ability to augment the immunogenicity of antigens (Liu and Guo, 2017, Kim et al., 2008). Keeping into consideration the immunoadjuvant role of $\alpha$-GalCer, we formulated $\alpha$-GalCer-MERS-PLpro-liposomes or MERS-PLpro-liposomes. Mice were injected with $\alpha$-GalCer-MERS-PLpro-liposomes or MERS-PLpro-liposomes, whereas the mice immunized with MERS-CoV-Alum used as a control. Mice immunized with $\alpha$-GalCer-Lip-MERS-PLpro-liposomes exhibited higher levels of effector and memory immune responses.

2. Materials and methods

2.1. Reagents

$\alpha$-GalCer, DPPC, cholesterol and ELISA kits were bought from Abcam (Cambridge, United Kingdom), whereas Phycoerythrin (PE)-conjugated PBS57-loaded CD1d tetramers were kindly provided by the Tetramer Core Facility of NIH (Atlanta, GA).

2.2. Expression and purification of MERS-CoV-PLpro

Middle East Respiratory Syndrome Coronavirus papain-like protease (MERS-CoV-PLpro) was expressed and purified by following the published procedure (Khan et al., 2022).

2.3. Preparation of liposomes and the entrapment of antigen

DPPC and Chol (7:3 M ratio) with or without $\alpha$-GalCer (24 $\mu$g) were used in the preparation of liposomes as described earlier (Khan et al., 2022). The characteristics of liposomes, including the size and polydispersity index (PDI) were determined by the Malvern Nano Zeta Sizer as described earlier (Khan et al., 2022).

2.4. Mice

Swiss female mice (25 ± 5 g) were used in the present study. Mice were taken from the animal house facility of the College of Applied Medical Sciences, Qassim University, Saudi Arabia. The experimental procedures were approved by the committee of research ethics, Deanship of Scientific Research, Qassim University, Buraydah, Saudi Arabia.

2.5. Determination of cyclophosphamide (CYP) - induced immune suppression

A dose of 100 mg/kg of cyclophosphamide (CYP) was injected into each mouse through the intraperitoneal route (Khan et al., 2021).

2.6. Immunization schedule

MERS-CoV PLpro (20 $\mu$g) encapsulated in liposomal formulations or emulsified with Alum was injected into each mouse through the subcutaneous route. Mice received two booster doses on days 14 and 21. Mice, which were immunized with the first dose of $\alpha$-GalCer-MERS-PLpro-liposomes, received two booster doses of MERS-PLpro-liposomes on days 14 and 21. Leukopenia induced in mice by injecting CYP (100 mg/kg) three days before each immunization dose. Mice were separated into six groups: 1. PBS, 2. Sham liposomes, 3. $\alpha$-GalCer-liposomes, 4. MERS-PLpro-liposomes, 5. $\alpha$-GalCer-MERS-PLpro-liposomes, 6. MERS-PLpro-Alum.

2.7. Determination of NKT cell activation in the spleen of the immunized mice

The status of NKT cell was determined by analyzing the splenocytes by using the cell titer 96 non-radioactive BrdU calorimetric ELISA kit (Abcam, Cambridge, UK) and following the instructions provided by the manufacturer (Khan et al., 2022).

2.8. Determination of IgG titer and the IgG isotypes

On day 5 post immunization, the blood was drawn through retro-orbital puncture and centrifuged at 1500 rpm to separate the serum. The status of antigen-specific IgG, IgG1 and IgG2a was estimated by the ELISA (Syed et al., 2003).

2.9. Determination of the proliferation of splenocytes

The proliferation assay of the splenocytes was performed by using the cell titer 96 non-radioactive BrdU calorimetric ELISA kit (Abcam, Cambridge, UK) and following the instructions provided by the manufacturer (Khan et al., 2022).

2.10. Determination of Th1 and Th2 cytokine

Three mice from were sacrificed to take out the spleen in order to prepare its single cell suspension as mentioned above. The cells were stimulated with 20 $\mu$g/ml of antigen and incubated for 48 h at 37°C. The cells stimulated with 20 $\mu$g/ml of ovalbumin were used...
as a control. The amounts of IFN-γ, IL-4, IL-12 and IL-13 were analyzed as described earlier (Khan et al., 2022).

2.11. Evaluation of long-term humoral and T cell memory immune response

After 150 days of the last immunization, a single dose of α-GalCer-MERS-PLpro-liposomes or MERS-PLpro-liposomes or MERS-PLpro-Alum was injected in mice in order to assess the memory immune response. Fresh mice (first time immunized) were used as a control. On days 0, 7, 14 and 21 post-immunization, the blood was taken to analyze the level of total IgG. The effect of booster dose was also measured by analyzing the proliferation of splenocytes as mentioned above.

2.12. Secretion of cytokines after a booster dose of immunization

The amounts of IFN-γ, IL-4, IL-12 and IL-13 were analyzed as described earlier (Khan et al., 2022).

2.13. Statistical analysis

The results were analyzed by one-way analysis of variance (ANOVA) using GraphPad Prism software, version 6.0 (La Jolla, CA, USA). The Turkey post-hoc test was performed to compare various groups. A value of p < 0.05 was considered statistically significant.

3. Results

3.1. Characterization of liposomes

The mean size of α-GalCer-MERS-PLpro-liposome was 139 nm and PDI value was found to be 0.265, whereas those of MERS-PLpro-liposomes were found to be 140 nm and 0.331.

3.2. CYP administration results in the depletion of the leukocyte numbers in the systemic circulation and spleen

The administration of CYP induced the condition of temporary leukopenia in the systemic circulation on days 3 and 5 post-CYP injection (Fig. 2A). The leukocytes started their recovery from day 7 and completely recovered to almost normal level by day 11 (Fig. 2A). Similarly, the numbers of splenocytes were reduced in CYP-injected mice on day 3, and thereafter started their recovery from day 5 post-CYP administration (Fig. 2B).

3.3. Administration of α-GalCer results in the proliferation of NKT cells

Mice immunized with α-GalCer-liposomes showed the activation of CD1d/α-GalCer + TCR-β positive splenocytes (Fig. 1, supplementary data).

3.4. Immunization with α-GalCer-MERS-PLpro-liposomes induced higher production of IgG and IgG2a isotype

There was the highest level of antibody titer in the sera of immunocompetent mice injected with α-GalCer-MERS-PLpro-liposomes followed by those immunized with MERS-PLpro-liposomes or MERS-PLpro-Alum (Fig. 3A). On the other hand, immunized leukopenic mice had lower antibody titer (Fig. 3A, 3B). Despite this, α-GalCer-MERS-PLpro-liposomes effectively stimulated greater antibody generation in leukopenic mice (Fig. 3B).

The ratio of IgG2a/IgG1 was 1.25 in the immunocompetent mice immunized with α-GalCer-MERS-PLpro-liposomes as compared to 1.05 and 0.89 in mice immunized with MERS-PLpro-liposomes or MERS-PLpro-Alum, respectively (Fig. 3C). The leukopenic mice immunized with α-GalCer-MERS-PLpro-liposomes had IgG2a/IgG1 equal to 1.05 (Fig. 3D).

3.5. Lymphocytes from α-GalCer-MERS-PLpro-liposomes immunized mice had increased proliferation

Immunization with α-GalCer-MERS-PLpro-liposomes resulted in a greater proliferation of splenocytes. On the contrary, the splenocytes from the leukopenic mice responded with lower proliferation (Fig. 4A, 4B). Importantly, the leukopenic mice immunized with α-GalCer-MERS-PLpro-liposomes showed greater proliferation of splenocytes as compared those immunized with MERS-PLpro-liposomes or MERS-PLpro-Alum (Fig. 4B).

3.6. Immunization with α-GalCer-MERS-PLpro-liposomes resulted in higher production of IFN-γ

The splenocytes from α-GalCer-MERS-PLpro-liposomes immunized mice produced 540 ± 88 pg/ml of IFN-γ, whereas those immunized with MERS-PLpro-liposomes secreted 215 ± 35 pg/ml (Fig. 5A). On the other hand, splenocytes from the leukopenic mice immunized with α-GalCer-MERS-PLpro-liposomes produced 302 ± 88 pg/ml of IFN-γ, whereas those immunized with MERS-

![Fig. 2. CYP administration induces leukopenia in (A) Blood, (B) Spleen. ** (p < 0.01) and *** (p < 0.001), Days post-CYP injection vs. day 0.](image-url)
PLpro-liposomes secreted 112 ± 28 pg/ml (Fig. 5B). IL-4 level was found to be 342 ± 58 pg/ml in immunocompetent mice immunized with α-GalCer-MERS-PLpro-liposomes followed by MERS-PLpro-liposomes and MERS-PLpro-Alum (Fig. 5C). However, the amount of IL-4 was found to be 418 ± 48 pg/ml in the leukopenic mice immunized with α-GalCer-MERS-PLpro-liposomes (Fig. 5D).

3.7. α-GalCer-MERS-PLpro-liposomes induced superior antibody memory immune response

The titer of of IgG increased much faster (25 fold) in α-GalCer-MERS-PLpro-liposomes immunized mice. On the other hand, the mice immunized with MERS-PLpro-liposomes and MERS-PLpro-alum had 15-fold and 12-fold IgG titer on day 14 (Fig. 6A). Interestingly, the leukopenic mice immunized with α-GalCer-MERS-PLpro-liposomes also responded well to a booster dose and had about 20-fold IgG titer (Fig. 6B).

3.8. Superior lymphocyte memory immune response in mice immunized with α-GalCer-MERS-PLpro-liposomes

A booster dose with α-GalCer-MERS-PLpro-liposomes induced higher proliferation of splenocytes as compared to those from MERS-PLpro-liposomes or MERS-PLpro-Alum immunized mice (Fig. 7A, 7B). However, the cells from immunocompetent mice immunized α-GalCer-MERS-PLpro-liposomes showed superior proliferation as compared to leukopenic mice.

3.9. Immunization with α-GalCer-MERS-PLpro-liposomes elicited higher secretion of cytokines

A booster dose with α-GalCer-MERS-PLpro-liposomes effectively stimulated the splenocytes that secreted greater amounts of IFN-γ, IL-12 and IL-13 (Supplementary Fig. 2).

4. Discussion

Immunocompromised persons need special attention in order to immunize them against viral infections. Cyclophosphamide administration induces marked immune suppression and affects a broad spectrum of immune cells, including T cells, dendritic cells, monocytes and neutrophils (Bao et al., 2020). Earlier studies demonstrated a lower number of leukocytes in CYP-injected humans (Giang et al., 1996). Thus, it is critical to develop a vaccine formulation that can effectively induce antigen-specific immune responses in immunocompromised subjects.
Due to the versatility of lipids, various types of liposomes can be formulated in order to incorporate a variety of antigenic molecules. Liposomized antigens can induce a greater immune response since they have the ability to release the antigen for a longer duration (Bernasconi et al., 2016). Moreover, liposomes can deliver antigens to APCs that cross present antigens to the cytotoxic T cells. It results in superior antigen-specific cell-mediated immune response (Dhakal and Renukaradhya, 2019; Tanaka et al., 2010). The incorporation of NKT ligands has been shown to increase the immunoadjuvant potential of liposomes resulting in the stimulation of antigen-specific CD8+ T cell responses (Bai et al., 2013; Grabowska et al., 2021).

In the current study, we measured the immunogenicity of MERS-CoV PLpro emulsified with Alum or loaded in α-GalCer-free liposomes or α-GalCer-containing liposomes in immunocompetent or leukopenic mice. Immunization with α-GalCer-MERS-PLpro-liposomes induced the proliferation of the NKT cells in the spleen of the mice owing to the presence of α-GalCer, whereas the mice immunized with MERS-PLpro-liposomes or MERS-PLpro-Alum did not. Vaccination with α-GalCer-MERS-PLpro-liposomes elicited higher production of antibodies as compared to those immunized with MERS-PLpro-liposomes or MERS-PLpro-Alum. α-GalCer has been reported to induce the proliferation of B cells, resulting in elevated production of antibodies (Chen et al., 2011; Rossignol et al., 2007). Notably, α-GalCer-MERS-PLpro-liposomes also augmented the production of antigen-specific antibodies in leukopenic mice. The status of a specific IgG isotype also contributes to an antiviral immunity. IgG1 contributes to Th2-type immunity, whereas IgG2a has a role in Th1-type of immunity that protects against viruses (Huber et al., 2006). Moreover, IgG2a monoclonal antibodies, not IgG1 monoclonal antibodies, can eliminate multiple viral infections (Huber et al., 2006). It suggests that IgG2a can also incite the effector immune responses. Whereas, IgG1 was reported to be a major isotype in serious COVID-19 patients. However, IgG2 isotype could not be detected in these patients (Luo et al., 2021). IgG2a isotype specific to influenza virus membrane protein M2 induced higher protection against viral infection as compared to IgG1 isotype (Van den Hoecke et al., 2017). The findings of this study illustrated that α-GalCer-MERS-PLpro-liposomes can switch IgG isotype to IgG2a in comparison to the immunization with MERS-PLpro-liposomes or MERS-PLpro-Alum. Furthermore, IgG2a has been reported to increase the proliferation of T cells, which are critical players in antiviral cell-mediated immunity (Getahun et al., 2004).

IFN-γ is an important antiviral cytokine that augments the killing activity of CD8+ T lymphocytes (Levy and García-Sastre, 2001). The splenocytes from α-GalCer-MERS-PLpro-liposomes immunized mice produced higher IFN-γ amounts that indicates the vaccine-induced antiviral immune response in the immunized mice. Furthermore, IFN-γ activates the NK cells and macrophages through the JAK-STAT signaling pathway (Mahallawi et al., 2018). Besides, IFN-γ has been shown to promote MHC class I-mediated antigen presentation (Zhou, 2009). Whereas, MERS-CoV infection antagonizes the expression of antigen presenting molecules (Menachery et al., 2018).

Interestingly, a booster dose with α-GalCer-MERS-PLpro-liposomes elicited strong memory immune responses. α-GalCer-MERS S-PLpro-liposomes elicited a remarkably greater antibody amounts and switching of IgG isotype to IgG2a. Memory T cell responses were assessed by analyzing T cell proliferation and the levels of Th1 and Th2 cytokines. The lymphocytes from the mice immunized with α-GalCer-MERS-PLpro-liposomes exhibited larger proliferation compared to the MERS-PLpro-liposomes or MERS-PLpro-Alum. IL-12 has been reported to have a role in IFN-γ secretion, and they together contribute to CTLs proliferation (Starbeck-Miller and Harty, 2015). IL-12 was also elevated in α-GalCer-MERS-PLpro-liposomes immunized mice. The administration of NKT cell ligands can induce the NKT cell anergy that limits the use of iNKT-cell agonists (Savage, 2014). This limitation can be overcome by incorporating α-GalCer into liposomes (Thapa et al., 2009). Therefore, α-GalCer-bearing liposomes can be used as effective immunoadjuvants to prepare an antiviral vaccine. Earlier...
studies evaluated the combination glycolipids and vaccine antigens against infectious diseases (Schmieg et al., 2003; Padte et al., 2011; Gonzalez-Aseguinolaza et al., 2002; Youn et al., 2007). The co-administration of 7DW8–5, an analog of α-GalCer, elevated malaria-antigen specific CTL response in primates (Padte et al., 2013).

These findings revealed that α-GalCer-MERS-PLpro-liposomes significantly enhanced MERS-CoV-PLpro-specific immune responses in immunocompetent and leukopenic mice. In addition, the splenocytes α-GalCer-MERS-PLpro-liposomes immunized mice produced larger amounts of IFN-γ that stimulates APCs and MHC class I expression. A booster dose with α-GalCer-MERS- PLpro-liposomes successfully rejuvenated the memory immune response. Thus, α-GalCer-MERS-PLpro-liposomes may ascertain to be a hopeful prophylactic preparation to protect immunocompromised persons against MERS-CoV infection. The results of iNKT cell-based vaccine formulations in mouse model can be extended and translated into human beings because of their certain common functional features in humans and mice. Future studies need to be conducted in order to develop a successful iNKT cell-based antiviral vaccine.

**Declaration of Competing Interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Acknowledgements

The authors gratefully acknowledge the Deanship of Scientific Research, Qassim University, for the financial support of this research study under the Interdisciplinary Grant No. 5575-cams1-2019-2-2-I during the 2019 academic year.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jksus.2022.102124.

References

Ahmad, N., Khan, M.A., Owais, M., 2001. Liposome mediated antigen delivery leads to induction of CD8+ T lymphocyte and antibody responses against the V3 loop region of HIV gp120. Cell. Immunol. 210 (1), 49–55.

Ashammari, M., Reynolds, K., Verhougstraete, M., O’Rourke, M., 2018. Comparison of perceived and observed hand hygiene compliance in healthcare workers in MERS-CoV endemic regions. Healthcare (Basel) 6 (4), 122.

Bai, L., Deng, S., Reboulet, R., Mathew, R., Teyton, L., Savage, P.B., Bendelac, A., 2013. Natural killer T (NKT)-B-cell interactions promote prolonged antibody responses and long-term memory to pneumococcal capsular polysaccharides. Proc. Natl. Acad. Sci. U. S. A. 110 (40), 16097–16102.

Bao, L., Hao, C., Wang, J., Wang, D., Zhao, Y., Li, Y., Yao, W., 2020. High-dose cyclophosphamide administration orchestrates phenotypic and functional alterations of immature dendritic cells and regulates Th cell polarization. Front. Pharmacol. 11, 775.

Bernasconi, V., Norling, K., Bally, M., Höök, F., Lycke, N.Y., 2016. Mucosal vaccine development based on liposome technology. J. Immunol. Res. 2016, 1–16.

Bosaeed, M., Kumar, D., 2018. Seasonal influenza vaccine in immunocompromised persons. Hum. Vaccin. Immunother. 14 (6), 1311–1322.

Brutkiewicz, R.R., 2006. CD1d ligands: the good, the bad, and the ugly. J. Immunol. 177 (2), 769–775.

Chen, Q., Mosovsky, K.L., Ross, A.C., 2011. Retinoic acid and α-galactosylceramide differentially regulate B cell activation in vitro and augment antibody production in vivo. Clin. Vaccine Immunol. 18 (6), 1015–1020.

Dhakal, S., Renukaradhya, G.J., 2019. Nanoparticle-based vaccine development and evaluation against viral infections in pigs. Vet. Res. 50 (1), 90.
Faridi, U., 2018. Middle East respiratory syndrome coronavirus (MERS-CoV): Impact on Saudi Arabia, 2015. Saudi J. Biol. Sci. 25 (7), 1402–1405.

Getahun, A., Dahlström, J., Wernersson, S., Heyman, B., 2004. IgG2a-mediated enhancement of antibody and T cell responses and its relation to inhibitory and activating Fc gamma receptors. J. Immunol. 172 (9), 5269–5276.

Giang, D.W., Goodman, A.D., Schiffer, R.B., Mattson, D.H., Petrie, M., Cohen, N., Ader, R., 1996. Conditioning of cyclophosphamide-induced leukopenia in humans. J. Neuropsychiatry Clin. Neurosci. 8 (2), 194–201.

González-Aseguínolaza, G., Van Kaer, L., Bergmann, C.C., Wilson, J.M., Schmieg, J., Kronenberg, M., Nakayama, T., Taniguchi, M., Koezuka, Y., Tsuji, M., 2002. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med. 195 (5), 617–624.

Grabowska, J., Stolk, D.A., Nijen Twilhaar, M.K., Ambrosini, M., Storm, G., van der Vliet, H.J., de Gruij, T.D., van Kooyk, Y., den Haan, J.M.M., 2021. Liposomal nanovaccine containing α-galactosylceramide and ganglioside GM3 stimulates robust CD8+ T cell responses via CD169 macrophages and cDC1. Vaccines (Basel) 9 (1), 56.

Gruber-Bauk, B., Simmons, A., Mayrhofer, G., Speck, P.G., 2003. Impaired clearance of herpes simplex virus type 1 from mice lacking CD1d or NKT cells expressing the semivariant V alpha 14-J alpha 281 TCR. J. Immunol. 170 (3), 1430–1434.

Khan, M.A., Khan, A., Alhumaydhi, F., Azam, F., Khan, S.H., Zofair, S.F.F., Ahmad, S., Younus, H., 2021. Liposomal alpha-gal acid alleviates cyclophosphamide-induced toxicity and eliminates the systemic Cryptococcus neoformans infection in leukopenic mice. Pharmaceuticals 13 (6), 882.

Khan, M.A., Khan, A., 2021. Role of NKT cells during viral infection and the development of NKT cell-based nanovaccines. Vaccines 9 (9), 949.

Khan, M.A., Malik, A., Alzohairy, M.A., Alrweewit, A.M., Alhatlani, B.Y., Rugaie, O.A., Khan, A., 2022. Liposome-mediated delivery of MERS antigen induces potent humoral and cell-mediated immune response in mice. Molecules 27 (2), 403.

Kim, S., Lalani, S., Parekh, V.V., Wu, L., Van Kaer, L., 2008. Glycolipid ligands of invariant natural killer T cells activate CD8+ T cell responses via CD169 macrophages and cDC1. Vaccine 25 (28), 5189–5198.

Liu, Z., Guo, J., 2017. MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape. Proc. Natl. Acad. Sci. U. S. A. 115 (5), E1012–E1021.

Padte, N.N., Li, X., Tsuji, M., Vasan, S., 2011. Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant. Clin. Immunol. 140 (2), 142–151.

Padte, N.N., Boente-Carrera, M., Andrews, C.D., McManus, J., Grasperge, B.F., Gettie, A., Coelho-dos-Reis, G.J., Li, X., Wu, D., Bruder, J.T., Sedegah, M., Patterson, N., Richie, T.L., Wong, C.-H., Ho, D.D., Vasan, S., Tsuji, M., Rodrigues, M., 2013. A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectorized malaria vaccine in non-human primates. PLoS ONE 8 (10), e78407.

Rossignol, A., Barra, A., Herbelin, A., Preud’homme, J.L., Combret, J.M., 2007. Freshly isolated Valpha24+ CD4+ invariant natural killer T cells activated by alpha-galactosylceramide-pulsed B cells promote both IgG and IgE production. Clin. Exp. Immunol. 148 (3), 555–563.

Savage, P.B., 2014. Vaccine development: NKT-cell adjuvants in conjugate. Nat. Chem. Biol. 10 (11), 882–883.

Schmieg, J., Yang, J., Franchk, R.W., Tsuji, M., 2003. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide. J. Exp. Med. 198 (11), 1631–1641.

Starbeck-Miller, G.R., Harty, J.T., 2015. The role of IL-12 and type I interferon in governing the magnitude of CD8 T cell responses. Adv. Exp. Med. Biol. 850, 31–41.

Syed, F.M., Khan, M.A., Nasti, T.H., Ahmad, N., Mohammad, O., 2003. Antigen entrapped in the escheriosomes leads to the generation of CD4+ helper and CD8+ cytotoxic T cell response. Vaccine 21 (19–20), 2383–2393.

Tandaka, Y., Taneichi, M., Kasai, M., Kakuchi, T., Uchida, T., 2010. Liposome-coupled antigens are internalized antigen-presenting cells via pinocytosis and cross-presented to CD8 T cells. PLoS ONE 5 (12), e15225.

Thapa, P., Zhang, G., Xia, C., Gelbard, A., Overwijk, W.W., Liu, C., Hwu, P., Chang, D.Z., Courtney, A., Sastry, J.K., Wang, P.C., Li, C., Zhou, D., 2009. Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. Vaccine 27 (25–26), 3484–3488.

Van den Hoecke, S., Ehrrhardt, K., Kolpe, A., El Bakkouri, K., Deng, L., Grotaert, H., Schoonus, S., Smet, A., Bentahir, M., Roose, K., Schotsaert, M., Schepens, B., Callewaert, N., Nimmerjahn, F., Staeheli, P., Hengel, H., Saelens, X., 2017. Hierarchical and redundant roles of activating FcγRs in antagonizing influenza disease by M2e-specific IgG1 and IgG2a antibodies. J. Virol. 91 (7), e02500–e3016.

Vora, S.B., Englund, J.A., 2015. Cytomegalovirus in immunocompromised children. Curr. Opin. Infect. Dis. 28 (4), 323–329.

You, H.J., Ko, S.Y., Lee, K.A., Ro, H.J., Lee, Y.S., Fujihashi, K., Boyaka, P.N., Kim, S.H., Horimoto, T., Kweon, M.N., Kang, C.Y., 2007. A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system. Vaccine 25 (28), 5189–5198.

Zhou, F., 2009. Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation. Int. Rev. Immunol. 28 (3–4), 239–260.